H Pham, H Torres, P Sharma - Urologic Oncology: Seminars and Original …, 2019 - Elsevier
Although the majority of bladder cancer literature has been dedicated to optimizing oncological outcomes and focuses on physical prognostic criteria such as nutritional and …
JA Witjes, T Lebret, EM Compérat, NC Cowan… - European urology, 2017 - Elsevier
Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …
JA Witjes, E Compérat, NC Cowan, M De Santis… - European urology, 2014 - Elsevier
Abstract Context The European Association of Urology (EAU) guidelines panel on Muscle- invasive and Metastatic bladder cancer (BCa) updates its guidelines yearly. This updated …
Background Little is known about health-related quality of life (HRQOL) following treatment for bladder cancer (BC). Objective To determine this, we undertook a cross-sectional survey …
LR Schover, M van der Kaaij, E van Dorst… - European journal of …, 2014 - Elsevier
Sexual dysfunction is a common consequence of cancer treatment, affecting at least half of men and women treated for pelvic malignancies and over a quarter of people with other …
R Mastroianni, G Tuderti, U Anceschi, AM Bove… - European urology …, 2022 - Elsevier
Background Open radical cystectomy (ORC) is still considered the reference approach for RC, although robot-assisted RC (RARC) has recently gained in popularity. There are …
Introduction Radical cystectomy and urinary diversion carries a high morbidity. Quality of life and body image are important considerations for urinary diversion (UD). We wanted to …
MA Cerruto, C D'Elia, S Siracusano, X Gedeshi… - European Journal of …, 2016 - Elsevier
Purpose The current literature on the impact of different urinary diversions on patients' health related quality of life (HR-QoL) showed a marginally better quality of life scores of orthotopic …
MD Tyson, DA Barocas - Urologic Clinics, 2018 - urologic.theclinics.com
Bladder cancer is the second most common genitourinary malignancy in the United States with an estimated incidence of approximately 11.6 cases per 100,000 per year. 1 …